Furthermore, aluminum consumption from vaccines is far less than that received from the diet or medications such as antacids (Baylor et al., 2002). Nonetheless, in recent years, the adjuvants received much attention because of the development of protein subunits made by rDNA technology (Hanes et al., 1997). The sub unit vaccines are weakly immunogenic when compared to whole-cell vaccines and therefore, need suitable adjuvants for delivering the antigens. Even though alum has good properties it is not much suitable for small proteins because the alum adsorbed vaccines elicit a short term immune response requiring many boosters for attaining minimum optimal threshold immune response. Consequently, it is necessary to find a new adjuvant that can replace the alum type adjuvant.
Give me a break Doc. Texas Pete (Bow-Tie) from Baylor.
limitation lacking as it does in inducing cyto toxic T-lymphocyte (CTL) responses especially to protect from viral infection (Doherty et al., 2006). Besides, there are well documented problems of aluminum adjuvant that induce inflammation and stimulate local production of erythema, granuloma, subcutaneous nodules and contact hypersensitivity (Men et al., 1995, Baylor et al., 2002) in addition to that alum cannot be frozen or lyophilized.
Market Data 
Markets 
AI
